Mechanism

HMG-CoA reductase inhibition → ↓ LDL and plaque inflammation.

Monitoring

Lipid panel, LFTs if symptomatic, CK if rhabdomyolysis suspected.

Guideline sources

• ACC/AHA Cardiovascular Guidelines

  Evidence-based cardiovascular risk reduction and therapy

• FDA Prescribing Information

  Indications, contraindications, monitoring, and boxed warnings

Pearls align with current society guidelines (ADA, ACC/AHA, IDSA, APA, ACOG, FDA labeling) — the same sources referenced in UpToDate monographs.

Mechanism

HMG-CoA reductase inhibition → ↓ LDL and plaque inflammation.

Monitoring

Lipid panel, LFTs if symptomatic, CK if rhabdomyolysis suspected.

Guideline sources

• ACC/AHA Cardiovascular Guidelines

  Evidence-based cardiovascular risk reduction and therapy

• FDA Prescribing Information

  Indications, contraindications, monitoring, and boxed warnings

Pearls align with current society guidelines (ADA, ACC/AHA, IDSA, APA, ACOG, FDA labeling) — the same sources referenced in UpToDate monographs.